BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younossi ZM. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg. 2005;15:310-315. [PMID: 15826462 DOI: 10.1381/0960892053576820] [Cited by in Crossref: 204] [Cited by in F6Publishing: 179] [Article Influence: 12.8] [Reference Citation Analysis]
Number Citing Articles
1 Diehl AM, Choi SS. The Liver in Type 2 Diabetes Mellitus. In: Feinglos MN, Bethel MA, editors. Type 2 Diabetes Mellitus. Totowa: Humana Press; 2008. pp. 351-64. [DOI: 10.1007/978-1-60327-043-4_21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Wu J, You J, Yerian L, Shiba A, Schauer PR, Sessler DI. Prevalence of Liver Steatosis and Fibrosis and the Diagnostic Accuracy of Ultrasound in Bariatric Surgery Patients. OBES SURG 2012;22:240-7. [DOI: 10.1007/s11695-011-0509-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
3 Drolz A, Wolter S, Wehmeyer MH, Piecha F, Horvatits T, Schulze Zur Wiesch J, Lohse AW, Mann O, Kluwe J. Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. Int J Obes (Lond) 2021. [PMID: 34168277 DOI: 10.1038/s41366-021-00881-8] [Reference Citation Analysis]
4 Widhalm K, Ghods E. Nonalcoholic fatty liver disease: a challenge for pediatricians. Int J Obes 2010;34:1451-67. [DOI: 10.1038/ijo.2010.185] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
5 Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, Rafiq N, Goodman Z, Chandhoke V, Baranova A. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg. 2008;18:1430-1437. [PMID: 18500507 DOI: 10.1007/s11695-008-9506-y] [Cited by in Crossref: 192] [Cited by in F6Publishing: 177] [Article Influence: 14.8] [Reference Citation Analysis]
6 Balakrishnan M, Patel P, Dunn-valadez S, Dao C, Khan V, Ali H, El-serag L, Hernaez R, Sisson A, Thrift AP, Liu Y, El-serag HB, Kanwal F. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2021;19:61-71.e15. [DOI: 10.1016/j.cgh.2020.04.067] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 24.0] [Reference Citation Analysis]
7 Chisholm J, Seki Y, Toouli J, Stahl J, Collins J, Kow L. Serologic predictors of nonalcoholic steatohepatitis in a population undergoing bariatric surgery. Surg Obes Relat Dis. 2012;8:416-422. [PMID: 21865094 DOI: 10.1016/j.soard.2011.06.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
8 Meneses D, Olveira A, Corripio R, del Carmen Méndez M, Romero M, Calvo-viñuelas I, Herranz L, Vicent D, de-Cos-Blanco AI. Performance of Noninvasive Liver Fibrosis Scores in the Morbid Obese Patient, Same Scores but Different Thresholds. OBES SURG 2020;30:2538-46. [DOI: 10.1007/s11695-020-04509-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
9 Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008;93:S74-S80. [PMID: 18987273 DOI: 10.1210/jc.2008-1399] [Cited by in Crossref: 176] [Cited by in F6Publishing: 167] [Article Influence: 14.7] [Reference Citation Analysis]
10 Lammers WJ, Tilburg AJV, Apers JA, Wiebolt J. Liver failure caused by prolonged state of malnutrition following bariatric surgery. World J Hepatol 2018; 10(3): 396-399 [PMID: 29599903 DOI: 10.4254/wjh.v10.i3.396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Sima A, Timar R, Vlad A, Timar B, Rosu M, Dan I, Sirli R, Popescu A, Sporea I. Nonalcoholic fatty liver disease: a frequent condition in type 2 diabetic patients. Wien Klin Wochenschr 2014;126:335-40. [PMID: 24652019 DOI: 10.1007/s00508-014-0530-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
12 Ciardullo S, Ronchetti C, Muraca E, Oltolini A, Perra S, Bianconi E, Zerbini F, Cannistraci R, Manzoni G, Gastaldelli A, Lattuada G, Perseghin G. Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD. J Endocrinol Invest 2020;43:1019-26. [PMID: 32008185 DOI: 10.1007/s40618-020-01188-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Adejumo AC, Cholankeril G, Iqbal U, Yoo ER, Boursiquot BC, Concepcion WC, Kim D, Ahmed A. Readmission Rates and Associated Outcomes for Alcoholic Hepatitis: A Nationwide Cohort Study. Dig Dis Sci 2020;65:990-1002. [PMID: 31372912 DOI: 10.1007/s10620-019-05759-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Younossi ZM, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N, Afendy A, Younoszai Z, Goodman Z, Baranova A. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg. 2011;21:431-439. [PMID: 20532833 DOI: 10.1007/s11695-010-0204-1] [Cited by in Crossref: 105] [Cited by in F6Publishing: 91] [Article Influence: 10.5] [Reference Citation Analysis]
15 Balmer ML, Siegrist K, Zimmermann A, Dufour J. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver International 2009;29:1184-8. [DOI: 10.1111/j.1478-3231.2009.02037.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
16 Williams KH, Viera de Ribeiro AJ, Prakoso E, Veillard AS, Shackel NA, Bu Y, Brooks B, Cavanagh E, Raleigh J, McLennan SV, McCaughan GW, Bachovchin WW, Keane FM, Zekry A, Twigg SM, Gorrell MD. Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity. Diabetes Res Clin Pract 2015;108:466-72. [PMID: 25836944 DOI: 10.1016/j.diabres.2015.02.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
17 Srivastava S, Younossi ZM. Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery. Hepatology 2005;42:490-2. [DOI: 10.1002/hep.20782] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
18 Ahmed U, Redgrave TG, Oates PS. Effect of dietary fat to produce non-alcoholic fatty liver in the rat. J Gastroenterol Hepatol. 2009;24:1463-1471. [PMID: 19702912 DOI: 10.1111/j.1440-1746.2009.05870.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
19 Rosenstengel S, Stoeppeler S, Bahde R, Spiegel HU, Palmes D. Type of steatosis influences microcirculation and fibrogenesis in different rat strains. J Invest Surg. 2011;24:273-282. [PMID: 22047200 DOI: 10.3109/08941939.2011.586094] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
20 Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine J, Tonascia J, Loomba R. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care. 2015;38:1347-1355. [PMID: 25887357 DOI: 10.2337/dc14-1239] [Cited by in Crossref: 101] [Cited by in F6Publishing: 83] [Article Influence: 16.8] [Reference Citation Analysis]
21 Solga SF, Alkhuraishe A, Cope K, Tabesh A, Clark JM, Torbenson M, Schwartz P, Magnuson T, Diehl AM, Risby TH. Breath biomarkers and non-alcoholic fatty liver disease: Preliminary observations. Biomarkers. 2006;11:174-183. [PMID: 16766393 DOI: 10.1080/13547500500421070] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
22 Trilk JL, Ortaglia A, Blair SN, Bottai M, Church TS, Pate RR. Cardiorespiratory fitness, waist circumference, and alanine aminotransferase in youth. Med Sci Sports Exerc. 2013;45:722-727. [PMID: 23190589 DOI: 10.1249/mss.0b013e31827aa875] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
23 Kanwar P, Kowdley KV. The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. Clin Liver Dis. 2016;20:225-243. [PMID: 27063266 DOI: 10.1016/j.cld.2015.10.002] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 8.3] [Reference Citation Analysis]
24 Yaturu S, Jain S. Obesity and Type 2 Diabetes. In: Preuss H, Bagchi D, editors. Obesity. CRC Press; 2007. pp. 139-54. [DOI: 10.1201/9781420005479.ch12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Pagadala M, Zein CO, Mccullough AJ. Predictors of Steatohepatitis and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease. Clinics in Liver Disease 2009;13:591-606. [DOI: 10.1016/j.cld.2009.07.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
26 Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care. 2006;9:637-642. [PMID: 16912563 DOI: 10.1097/01.mco.0000241677.40170.17] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 5.1] [Reference Citation Analysis]
27 Huang H, Lin W, Lee L, Wang H, Lee W, Huang K. Metabolic Syndrome Is Related to Nonalcoholic Steatohepatitis in Severely Obese Subjects. OBES SURG 2007;17:1457-63. [DOI: 10.1007/s11695-008-9423-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
28 Seki Y, Kakizaki S, Horiguchi N, Hashizume H, Tojima H, Yamazaki Y, Sato K, Kusano M, Yamada M, Kasama K. Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery. J Gastroenterol. 2016;51:281-289. [PMID: 26314837 DOI: 10.1007/s00535-015-1114-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
29 Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45:600-606. [PMID: 16899321 DOI: 10.1016/j.jhep.2006.06.013] [Cited by in Crossref: 340] [Cited by in F6Publishing: 299] [Article Influence: 22.7] [Reference Citation Analysis]
30 Tuyama AC, Chang CY. Non-alcoholic fatty liver disease: Non-alcoholic fatty liver disease. Journal of Diabetes 2012;4:266-80. [DOI: 10.1111/j.1753-0407.2012.00204.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
31 de Avelar CR, Pereira EM, de Farias Costa PR, de Jesus RP, de Oliveira LPM. Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis. World J Gastroenterol 2017; 23(27): 5004-5017 [PMID: 28785154 DOI: 10.3748/wjg.v23.i27.5004] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
32 Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008; 14(2): 193-199 [PMID: 18186554 DOI: 10.3748/wjg.14.193] [Cited by in CrossRef: 214] [Cited by in F6Publishing: 197] [Article Influence: 16.5] [Reference Citation Analysis]
33 Qureshi K, Clements RH, Abrams GA. The Utility of the “NAFLD Fibrosis Score” in Morbidly Obese Subjects with NAFLD. OBES SURG 2008;18:264-70. [DOI: 10.1007/s11695-007-9295-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
34 Ham JR, Choi RY, Lee Y, Lee MK. Effects of Edible Insect Tenebrio molitor Larva Fermentation Extract as a Substitute Protein on Hepatosteatogenesis and Proteomic Changes in Obese Mice Induced by High-Fat Diet. Int J Mol Sci 2021;22:3615. [PMID: 33807173 DOI: 10.3390/ijms22073615] [Reference Citation Analysis]
35 Ong JP, Younossi ZM. Approach to the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2005;9:617-34. [DOI: 10.1016/j.cld.2005.07.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
36 Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020;323:1175-1183. [PMID: 32207804 DOI: 10.1001/jama.2020.2298] [Cited by in Crossref: 119] [Cited by in F6Publishing: 116] [Article Influence: 119.0] [Reference Citation Analysis]
37 Estep M, Armistead D, Hossain N, Elarainy H, Goodman Z, Baranova A, Chandhoke V, Younossi ZM. Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010;32:487-497. [PMID: 20497147 DOI: 10.1111/j.1365-2036.2010.04366.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 8.4] [Reference Citation Analysis]
38 Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, Goodman Z. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874-1882. [PMID: 21360720 DOI: 10.1002/hep.24268] [Cited by in Crossref: 401] [Cited by in F6Publishing: 357] [Article Influence: 40.1] [Reference Citation Analysis]
39 Ciupińska-Kajor M, Hartleb M, Kajor M, Kukla M, Wyleżoł M, Lange D, Liszka L. Hepatic angiogenesis and fibrosis are common features in morbidly obese patients. Hepatol Int 2013;7:233-40. [PMID: 23519653 DOI: 10.1007/s12072-011-9320-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
40 Lee SJ, Heinrich G, Fedorova L, Al-Share QY, Ledford KJ, Fernstrom MA, McInerney MF, Erickson SK, Gatto-Weis C, Najjar SM. Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule 1 mutant mice. Gastroenterology 2008;135:2084-95. [PMID: 18848945 DOI: 10.1053/j.gastro.2008.08.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
41 Colak Y, Tuncer I, Senates E, Ozturk O, Doganay L, Yilmaz Y. Nonalcoholic Fatty Liver Disease: A Nutritional Approach. Metabolic Syndrome and Related Disorders 2012;10:161-6. [DOI: 10.1089/met.2011.0145] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
42 Palmer M. Nonalcoholic Fatty Liver Disease. In: Mullin GE, Cheskin LJ, Matarese LE, editors. Integrative Weight Management. New York: Springer; 2014. pp. 145-69. [DOI: 10.1007/978-1-4939-0548-5_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
43 Petrick A, Benotti P, Wood GC, Still CD, Strodel WE, Gabrielsen J, Rolston D, Chu X, Argyropoulos G, Ibele A, Gerhard GS. Utility of Ultrasound, Transaminases, and Visual Inspection to Assess Nonalcoholic Fatty Liver Disease in Bariatric Surgery Patients. Obes Surg 2015;25:2368-75. [PMID: 26003548 DOI: 10.1007/s11695-015-1707-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
44 Jouët P, Sabaté J, Maillard D, Msika S, Mechler C, Ledoux S, Harnois F, Coffin B. Relationship between Obstructive Sleep Apnea and Liver Abnormalities in Morbidly Obese Patients: A Prospective Study. OBES SURG 2007;17:478-85. [DOI: 10.1007/s11695-007-9085-3] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 4.2] [Reference Citation Analysis]
45 Hung CK, Bodenheimer HC Jr. Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clin Liver Dis 2018;22:175-87. [PMID: 29128055 DOI: 10.1016/j.cld.2017.08.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
46 Ong JP, Younossi ZM. Epidemiology and Natural History of NAFLD and NASH. Clinics in Liver Disease 2007;11:1-16. [DOI: 10.1016/j.cld.2007.02.009] [Cited by in Crossref: 292] [Cited by in F6Publishing: 272] [Article Influence: 20.9] [Reference Citation Analysis]
47 Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009;51:371-9. [PMID: 19501928 DOI: 10.1016/j.jhep.2009.03.019] [Cited by in Crossref: 353] [Cited by in F6Publishing: 330] [Article Influence: 29.4] [Reference Citation Analysis]
48 Losekann A, Weston AC, de Mattos AA, Tovo CV, de Carli LA, Espindola MB, Pioner SR, Coral GP. Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients. Int J Mol Sci. 2015;16:25552-25559. [PMID: 26512661 DOI: 10.3390/ijms161025552] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
49 Zain SM, Mohamed Z, Mahadeva S, Rampal S, Basu RC, Cheah PL, Salim A, Mohamed R. Susceptibility and gene interaction study of the angiotensin II type 1 receptor (AGTR1) gene polymorphisms with non-alcoholic fatty liver disease in a multi-ethnic population. PLoS One. 2013;8:e58538. [PMID: 23484035 DOI: 10.1371/journal.pone.0058538] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
50 Daniel S, Soleymani T, Garvey WT. A complications-based clinical staging of obesity to guide treatment modality and intensity. Curr Opin Endocrinol Diabetes Obes 2013;20:377-88. [PMID: 23974764 DOI: 10.1097/01.med.0000433067.01671.f5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
51 Najt CP, Senthivinayagam S, Aljazi MB, Fader KA, Olenic SD, Brock JR, Lydic TA, Jones AD, Atshaves BP. Liver-specific loss of Perilipin 2 alleviates diet-induced hepatic steatosis, inflammation, and fibrosis. Am J Physiol Gastrointest Liver Physiol 2016;310:G726-38. [PMID: 26968211 DOI: 10.1152/ajpgi.00436.2015] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 11.6] [Reference Citation Analysis]
52 Sukahri S, Mohamed Shah FZ, Ismail AI, Koshy M, Johari B, Mohd Razali M, Abdul Rahman TH, Isa MR, Abdul Ghani R. Significantly higher atherosclerosis risks in patients with obstructive sleep apnea and non-alcoholic fatty liver disease. PLoS One 2021;16:e0253298. [PMID: 34191823 DOI: 10.1371/journal.pone.0253298] [Reference Citation Analysis]
53 Lee HW, Park SY, Kim SU, Jang JY, Park H, Kim JK, Lee CK, Chon YE, Han KH. Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease. PLoS One. 2016;11:e0157358. [PMID: 27284700 DOI: 10.1371/journal.pone.0157358] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 7.6] [Reference Citation Analysis]
54 Ulitsky A, Ananthakrishnan AN, Komorowski R, Wallace J, Surapaneni SN, Franco J, Saeian K, Gawrieh S. A Noninvasive Clinical Scoring Model Predicts Risk of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. OBES SURG 2010;20:685-91. [DOI: 10.1007/s11695-010-0118-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
55 Ramos-Lopez O, Martinez-Lopez E, Roman S, Fierro NA, Panduro A. Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico. World J Gastroenterol 2015; 21(41): 11552-11566 [PMID: 26556986 DOI: 10.3748/wjg.v21.i41.11552] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
56 Okazaki I, Noro T, Tsutsui N, Yamanouchi E, Kuroda H, Nakano M, Yokomori H, Inagaki Y. Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs). Cancers (Basel). 2014;6:1220-1255. [PMID: 24978432 DOI: 10.3390/cancers6031220] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
57 Grgurevic I, Podrug K, Mikolasevic I, Kukla M, Madir A, Tsochatzis EA. Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. Can J Gastroenterol Hepatol 2020;2020:9181368. [PMID: 32051820 DOI: 10.1155/2020/9181368] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
58 Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006;55:1650-60. [PMID: 17047111 DOI: 10.1136/gut.2006.091454] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 5.9] [Reference Citation Analysis]
59 Yang A, Nguyen M, Ju I, Brancatisano A, Ryan B, van der Poorten D. Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery. Sci Rep 2021;11:14006. [PMID: 34234198 DOI: 10.1038/s41598-021-93294-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Kim JY, Lee C, Oh M, Im J, Lee J, Chu SH, Lee H, Jeon JY. Relationship between non-alcoholic fatty liver disease, metabolic syndrome and insulin resistance in Korean adults: A cross-sectional study. Clinica Chimica Acta 2016;458:12-7. [DOI: 10.1016/j.cca.2016.03.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
61 Smit C, De Hoogd S, Brüggemann RJM, Knibbe CAJ. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol 2018;14:275-85. [PMID: 29431542 DOI: 10.1080/17425255.2018.1440287] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 15.7] [Reference Citation Analysis]
62 Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29:113-119. [PMID: 18384521 DOI: 10.1111/j.1478-3231.2008.01718.x] [Cited by in Crossref: 304] [Cited by in F6Publishing: 285] [Article Influence: 23.4] [Reference Citation Analysis]
63 燕云, 赵红霞, 潘红星. 工作餐人群血糖和血脂的变化. 世界华人消化杂志 2006; 14(20): 2037-2039 [DOI: 10.11569/wcjd.v14.i20.2037] [Reference Citation Analysis]
64 Khandelwal R, Dassanayake AS, Conjeevaram HS, Singh SP. Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist? World J Diabetes 2021; 12(9): 1479-1493 [PMID: 34630901 DOI: 10.4239/wjd.v12.i9.1479] [Reference Citation Analysis]
65 Tarantino G. Is NAFLD an incidentaloma? Gastroenterology 2006;130:1014-5. [PMID: 16530549 DOI: 10.1053/j.gastro.2006.01.077] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
66 Elam MB, Cowan GS Jr, Rooney RJ, Hiler ML, Yellaturu CR, Deng X, Howell GE, Park EA, Gerling IC, Patel D, Corton JC, Cagen LM, Wilcox HG, Gandhi M, Bahr MH, Allan MC, Wodi LA, Cook GA, Hughes TA, Raghow R. Hepatic gene expression in morbidly obese women: implications for disease susceptibility. Obesity (Silver Spring) 2009;17:1563-73. [PMID: 19265796 DOI: 10.1038/oby.2009.49] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
67 Rachakonda VP, Reeves VL, Aljammal J, Wills RC, Trybula JS, DeLany JP, Kienesberger PC, Kershaw EE. Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity. Obesity (Silver Spring). 2015;23:965-972. [PMID: 25865747 DOI: 10.1002/oby.20960] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
68 de Carli MA, de Carli LA, Correa MB, Junqueira G, Tovo CV, Coral GP. Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2020;32:420-5. [DOI: 10.1097/meg.0000000000001519] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
69 Salman AA, Aboelfadl SA, Heagzy MA. New Era for Usage of Serum Liver Enzymes as A Promising Horizon for the Prediction of Non-Alcoholic Fatty Liver Disease. Open Access Maced J Med Sci 2016;4:348-52. [PMID: 27703554 DOI: 10.3889/oamjms.2016.092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
70 Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Rep 2020;2:100192. [PMID: 33163950 DOI: 10.1016/j.jhepr.2020.100192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
71 Carulli L, Ballestri S, Lonardo A, Lami F, Violi E, Losi L, Bonilauri L, Verrone AM, Odoardi MR, Scaglioni F. Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? Intern Emerg Med. 2013;8:297-305. [PMID: 21559749 DOI: 10.1007/s11739-011-0609-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 4.7] [Reference Citation Analysis]
72 Simo KA, McKillop IH, McMillan MT, Ahrens WA, Walters AL, Thompson KJ, Kuwada TS, Martinie JB, Iannitti DA, Gersin KS, Sindram D. Does a calculated "NAFLD fibrosis score" reliably negate the need for liver biopsy in patients undergoing bariatric surgery? Obes Surg. 2014;24:15-21. [PMID: 23934335 DOI: 10.1007/s11695-013-1044-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
73 Argentou M, Tiniakos DG, Karanikolas M, Melachrinou M, Makri MG, Kittas C, Kalfarentzos F. Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. Obes Surg. 2009;19:1313-1323. [PMID: 19693638 DOI: 10.1007/s11695-009-9912-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
74 Kimura Y, Hyogo H, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K. Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. J Gastroenterol Hepatol 2011;26:517-22. [PMID: 21054523 DOI: 10.1111/j.1440-1746.2010.06567.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
75 Aron-wisnewsky J, Minville C, Tordjman J, Lévy P, Bouillot J, Basdevant A, Bedossa P, Clément K, Pépin J. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. Journal of Hepatology 2012;56:225-33. [DOI: 10.1016/j.jhep.2011.04.022] [Cited by in Crossref: 143] [Cited by in F6Publishing: 124] [Article Influence: 15.9] [Reference Citation Analysis]
76 Søgaard KK, Horváth-Puhó E, Grønbaek H, Jepsen P, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol. 2009;104:96-101. [PMID: 19098856 DOI: 10.1038/ajg.2008.34] [Cited by in Crossref: 274] [Cited by in F6Publishing: 220] [Article Influence: 22.8] [Reference Citation Analysis]
77 George ES, Roberts SK, Nicoll AJ, Reddy A, Paris T, Itsiopoulos C, Tierney AC. Non-alcoholic fatty liver disease patients attending two metropolitan hospitals in Melbourne, Australia: high risk status and low prevalence. Intern Med J 2018;48:1369-76. [PMID: 29845719 DOI: 10.1111/imj.13973] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
78 Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, Tiwari U, Ferrel L, Pabst M, Bass NM, Merriman RB. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology. 2008;47:1916-1923. [PMID: 18433022 DOI: 10.1002/hep.22241] [Cited by in Crossref: 105] [Cited by in F6Publishing: 101] [Article Influence: 8.1] [Reference Citation Analysis]
79 Gentile CL, Frye M, Pagliassotti MJ. Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease. Antioxid Redox Signal. 2011;15:505-521. [PMID: 21128705 DOI: 10.1089/ars.2010.3790] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 6.7] [Reference Citation Analysis]
80 Pathak S, Tang J, Terlizzo M, Poston G, Malik HZ. Hepatic steatosis, body mass index and long term outcome in patients undergoing hepatectomy for colorectal liver metastases. European Journal of Surgical Oncology (EJSO) 2010;36:52-7. [DOI: 10.1016/j.ejso.2009.09.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
81 Barbois S, Arvieux C, Leroy V, Reche F, Stürm N, Borel A. Benefit–risk of intraoperative liver biopsy during bariatric surgery: review and perspectives. Surgery for Obesity and Related Diseases 2017;13:1780-6. [DOI: 10.1016/j.soard.2017.07.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
82 Younossi ZM. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation. Liver Transpl 2018;24:166-70. [PMID: 29272073 DOI: 10.1002/lt.25003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
83 Stepanova M, Hossain N, Afendy A, Perry K, Goodman ZD, Baranova A, Younossi Z. Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease. Obes Surg. 2010;20:640-650. [PMID: 20119733 DOI: 10.1007/s11695-010-0078-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
84 Baldwin D, Chennakesavalu M, Gangemi A. Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria. Surg Obes Relat Dis 2019;15:2123-30. [PMID: 31711944 DOI: 10.1016/j.soard.2019.09.060] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
85 Estep JM, Baranova A, Hossain N, Elariny H, Ankrah K, Afendy A, Chandhoke V, Younossi ZM. Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis. Obes Surg. 2009;19:617-624. [PMID: 19280268 DOI: 10.1007/s11695-009-9814-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
86 Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert Review of Gastroenterology & Hepatology 2014;5:189-200. [DOI: 10.1586/egh.11.21] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 8.0] [Reference Citation Analysis]
87 Tang G, Xu Y, Zhang C, Wang N, Li H, Feng Y. Green Tea and Epigallocatechin Gallate (EGCG) for the Management of Nonalcoholic Fatty Liver Diseases (NAFLD): Insights into the Role of Oxidative Stress and Antioxidant Mechanism. Antioxidants (Basel) 2021;10:1076. [PMID: 34356308 DOI: 10.3390/antiox10071076] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Lorbek G, Urlep Ž, Rozman D. Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease. Pharmacogenomics 2016;17:1273-88. [PMID: 27377717 DOI: 10.2217/pgs-2016-0047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
89 Hegazy MA, Samy MA, Tawfik A, Naguib MM, Ezzat A, Behiry ME. Abdominal subcutaneous fat thickness and homeostasis model assessment of insulin resistance as simple predictors of nonalcoholic steatohepatitis. Diabetes Metab Syndr Obes 2019;12:1105-11. [PMID: 31372020 DOI: 10.2147/DMSO.S202343] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
90 Chtioui H, Semela D, Ledermann M, Zimmermann A, Dufour JF. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Liver Int. 2007;27:764-771. [PMID: 17617119 DOI: 10.1111/j.1478-3231.2007.01524.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
91 Zein CO, Beatty K, Post AB, Logan L, Debanne S, McCullough AJ. Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology 2006;44:1564-71. [PMID: 17133468 DOI: 10.1002/hep.21423] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 4.9] [Reference Citation Analysis]
92 de Freitas Júnior JR, Ribeiro IB, de Moura DTH, Sagae VMT, de Souza GMV, de Oliveira GHP, Sánchez-Luna SA, de Souza TF, de Moura ETH, de Oliveira CPMS, Bernardo WM, de Moura EGH. Effects of intragastric balloon placement in metabolic dysfunction-associated fatty liver disease: A systematic review and meta-analysis. World J Hepatol 2021; 13(7): 815-829 [PMID: 34367502 DOI: 10.4254/wjh.v13.i7.815] [Reference Citation Analysis]
93 Almeida AM, Cotrim HP, Barbosa DBV, Athayde LGM, Santos AS, Bitencourt AGV, Freitas LAR, Rios A, Alves E. Fatty liver disease in severe obese patients: Diagnostic value of abdominal ultrasound. World J Gastroenterol 2008; 14(9): 1415-1418 [PMID: 18322958 DOI: 10.3748/wjg.14.1415] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 62] [Article Influence: 4.8] [Reference Citation Analysis]
94 Reynaert H, Geerts A, Henrion J. Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones. Aliment Pharmacol Ther 2005;22:897-905. [DOI: 10.1111/j.1365-2036.2005.02682.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
95 Liu K, Mccaughan GW. Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 3-18. [DOI: 10.1007/978-981-10-8684-7_2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
96 Jump DB, Depner CM, Tripathy S, Lytle KA. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer. Adv Nutr 2015;6:694-702. [PMID: 26567194 DOI: 10.3945/an.115.009423] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
97 Cuenza LR, Razon TLJ, Dayrit JC. Correlation between severity of ultrasonographic nonalcoholic fatty liver disease and cardiometabolic risk among Filipino wellness patients. J Cardiovasc Thorac Res 2017;9:85-9. [PMID: 28740627 DOI: 10.15171/jcvtr.2017.14] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
98 Langella S, Russolillo N, Forchino F, Lo Tesoriere R, D'eletto M, Ferrero A. Impact of obesity on postoperative outcome of hepatic resection for colorectal metastases. Surgery 2015;158:1521-9. [DOI: 10.1016/j.surg.2015.07.024] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
99 Han ML, Lee WJ, Chen JC, Ser KH, Chen SC, Lee YC. Clinical Characteristics and Outcome of Morbidly Obese Bariatric Patients with Concurrent Hepatitis C Viral Infection. Obes Surg 2019;29:828-34. [PMID: 30536020 DOI: 10.1007/s11695-018-3615-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Ratziu V, Martin L, Fedchuk L, Poynard T. Can nonalcoholic steatohepatitis be diagnosed without liver biopsy? Biomark Med 2009;3:353-61. [PMID: 20477484 DOI: 10.2217/bmm.09.36] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
101 Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Unalp A; NASH Clinical Research Network. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 2008;48:829-34. [PMID: 18321606 DOI: 10.1016/j.jhep.2008.01.016] [Cited by in Crossref: 137] [Cited by in F6Publishing: 127] [Article Influence: 10.5] [Reference Citation Analysis]
102 Hyysalo J, Männistö VT, Zhou Y, Arola J, Kärjä V, Leivonen M, Juuti A, Jaser N, Lallukka S, Käkelä P. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol. 2014;60:839-846. [PMID: 24333862 DOI: 10.1016/j.jhep.2013.12.009] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 9.5] [Reference Citation Analysis]
103 Liang RJ, Wang HH, Lee WJ, Liew PL, Lin JT, Wu MS. Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. Obes Surg. 2007;17:45-56. [PMID: 17355768 DOI: 10.1007/s11695-007-9005-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
104 Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010;3:121-37. [PMID: 21180596 DOI: 10.1177/1756283X09359964] [Cited by in Crossref: 70] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
105 Ricardo de Andrade A, Cotrim HP, Alves E, Soares D, Rocha R, Almeida A, Almeida CG, Antonio de Freitas L. Nonalcoholic fatty liver disease in severely obese individuals: The influence of bariatric surgery. Annals of Hepatology 2008;7:364-8. [DOI: 10.1016/s1665-2681(19)31838-1] [Cited by in Crossref: 22] [Article Influence: 1.7] [Reference Citation Analysis]
106 Baranova A, Schlauch K, Elariny H, Jarrar M, Bennett C, Nugent C, Gowder SJ, Younoszai Z, Collantes R, Chandhoke V, Younossi ZM. Gene Expression Patterns in Hepatic Tissue and Visceral Adipose Tissue of Patients with Non-Alcoholic Fatty Liver Disease. OBES SURG 2007;17:1111-8. [DOI: 10.1007/s11695-007-9187-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
107 Ghoghaei M, Taghdiri F, Khajeh E, Azmoudeh Ardalan F, Sedaghat M, Hosseini Shirvani S, Zarei S, Toolabi K. Parathyroid Hormone Levels May Predict Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Hepat Mon 2015;15:e29697. [PMID: 26300934 DOI: 10.5812/hepatmon.29697v2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
108 Younossi ZM, McCullough AJ. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int. 2009;29 Suppl 2:3-12. [PMID: 19187068 DOI: 10.1111/j.1478-3231.2008.01949.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
109 Baranova A, Younossi ZM. Adipokines in Non-Alcoholic Fatty Liver Disease. In: Fantuzzi G, Mazzone T, editors. Adipose Tissue and Adipokines in Health and Disease. Totowa: Humana Press; 2007. pp. 291-305. [DOI: 10.1007/978-1-59745-370-7_22] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
110 Younossi Z, Henry L. Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. Gastroenterology. 2016;150:1778-1785. [PMID: 26980624 DOI: 10.1053/j.gastro.2016.03.005] [Cited by in Crossref: 141] [Cited by in F6Publishing: 122] [Article Influence: 28.2] [Reference Citation Analysis]
111 Chen Z, Qin H, Qiu S, Chen G, Chen Y. Correlation of triglyceride to high-density lipoprotein cholesterol ratio with nonalcoholic fatty liver disease among the non-obese Chinese population with normal blood lipid levels: a retrospective cohort research. Lipids Health Dis 2019;18:162. [PMID: 31399032 DOI: 10.1186/s12944-019-1104-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
112 Anderson N, Borlak J. Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis. Pharmacol Rev 2008;60:311-57. [DOI: 10.1124/pr.108.00001] [Cited by in Crossref: 260] [Cited by in F6Publishing: 247] [Article Influence: 20.0] [Reference Citation Analysis]
113 Le D, Marks D, Lyle E, Corless CL, Diggs BS, Jobe BA, Kay T, Deveney CW, Wolfe BM, Roberts CT. Serum leptin levels, hepatic leptin receptor transcription, and clinical predictors of non-alcoholic steatohepatitis in obese bariatric surgery patients. Surg Endosc. 2007;21:1593-1599. [PMID: 17294310 DOI: 10.1007/s00464-006-9185-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
114 Wachtel MS, Zhang Y, Kaye KE, Chiriva-internati M, Frezza EE. Increased Age, Male Gender, and Cirrhosis, but Not Steatosis or a Positive Viral Serology, Negatively Impact the Life Expectancy of Patients who Undergo Liver Biopsy. Dig Dis Sci 2007;52:2276-81. [DOI: 10.1007/s10620-006-9715-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
115 Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci 2021;271:119220. [PMID: 33592199 DOI: 10.1016/j.lfs.2021.119220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
116 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
117 Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. Transplantation. 2019;103:22-27. [PMID: 30335697 DOI: 10.1097/tp.0000000000002484] [Cited by in Crossref: 120] [Cited by in F6Publishing: 57] [Article Influence: 60.0] [Reference Citation Analysis]
118 Kroh M, Liu R, Chand B. Laparoscopic bariatric surgery: what else are we uncovering? Liver pathology and preoperative indicators of advanced liver disease in morbidly obese patients. Surg Endosc 2007;21:1957-60. [PMID: 17479322 DOI: 10.1007/s00464-007-9351-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
119 Lytle KA, Bush NC, Triay JM, Kellogg TA, Kendrick ML, Swain JM, Gathaiya NW, Hames KC, Jensen MD. Hepatic Fatty Acid Balance and Hepatic Fat Content in Humans With Severe Obesity. J Clin Endocrinol Metab 2019;104:6171-81. [PMID: 31408176 DOI: 10.1210/jc.2019-00875] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
120 Wolter S, Duprée A, Coelius C, El Gammal A, Kluwe J, Sauer N, Mann O. Influence of Liver Disease on Perioperative Outcome After Bariatric Surgery in a Northern German Cohort. Obes Surg 2017;27:90-5. [PMID: 27272667 DOI: 10.1007/s11695-016-2253-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
121 Agrawal S, Duseja AK. Non-alcoholic Fatty Liver Disease: East Versus West. J Clin Exp Hepatol 2012;2:122-34. [PMID: 25755421 DOI: 10.1016/S0973-6883(12)60101-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
122 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
123 Armandi A, Bugianesi E. Natural history of NASH. Liver Int 2021;41 Suppl 1:78-82. [PMID: 34155792 DOI: 10.1111/liv.14910] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
124 Argo CK, Caldwell SH. Epidemiology and Natural History of Non-Alcoholic Steatohepatitis. Clinics in Liver Disease 2009;13:511-31. [DOI: 10.1016/j.cld.2009.07.005] [Cited by in Crossref: 247] [Cited by in F6Publishing: 223] [Article Influence: 20.6] [Reference Citation Analysis]
125 Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM. Adipokines and cytokines in non-alcoholic fatty liver disease: ADIPOKINES AND CYTOKINES IN NAFLD. Alimentary Pharmacology & Therapeutics 2008;27:412-21. [DOI: 10.1111/j.1365-2036.2007.03586.x] [Cited by in Crossref: 284] [Cited by in F6Publishing: 275] [Article Influence: 20.3] [Reference Citation Analysis]
126 Wang Z, Xu M, Hu Z, Hultström M, Lai E. Sex-specific prevalence of fatty liver disease and associated metabolic factors in Wuhan, south central China. Eur J Gastroenterol Hepatol 2014;26:1015-21. [PMID: 25003744 DOI: 10.1097/MEG.0000000000000151] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
127 Venkatesh SK, Hennedige T, Johnson GB, Hough DM, Fletcher JG. Imaging patterns and focal lesions in fatty liver: a pictorial review. Abdom Radiol (NY) 2017;42:1374-92. [PMID: 27999887 DOI: 10.1007/s00261-016-1002-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
128 Praveen Raj P, Gomes RM, Kumar S, Senthilnathan P, Karthikeyan P, Shankar A, Palanivelu C. The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: "NASHOST" prospective observational trial. Surg Obes Relat Dis. 2015;11:1315-1322. [PMID: 26003897 DOI: 10.1016/j.soard.2015.02.006] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 9.0] [Reference Citation Analysis]
129 Zelber-Sagi S, Shoham D, Zvibel I, Abu-Abeid S, Shibolet O, Fishman S. Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients. World J Hepatol 2017; 9(2): 91-98 [PMID: 28144390 DOI: 10.4254/wjh.v9.i2.91] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
130 Ciocan D, Lebrun A, Lamouri K, Pourcher G, Voican C, Njiké-nakseu M, Ferretti S, Courie R, Tranchart H, Balian A, Prévot S, Perlemuter G, Dagher I, Naveau S. Adaptation of liver stiffness measurement depth in bariatric surgery candidates with suspected nonalcoholic fatty liver disease: . European Journal of Gastroenterology & Hepatology 2016;28:1014-20. [DOI: 10.1097/meg.0000000000000671] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
131 Calès P, Lainé F, Boursier J, Deugnier Y, Moal V, Oberti F, Hunault G, Rousselet MC, Hubert I, Laafi J. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol. 2009;50:165-173. [PMID: 18977552 DOI: 10.1016/j.jhep.2008.07.035] [Cited by in Crossref: 170] [Cited by in F6Publishing: 139] [Article Influence: 13.1] [Reference Citation Analysis]
132 Nahra R, Wang T, Gadde KM, Oscarsson J, Stumvoll M, Jermutus L, Hirshberg B, Ambery P. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Diabetes Care 2021:dc202151. [PMID: 34016612 DOI: 10.2337/dc20-2151] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
133 Ali AH, Petroski GF, Diaz-Arias AA, Al Juboori A, Wheeler AA, Ganga RR, Pitt JB, Spencer NM, Hammoud GM, Rector RS, Parks EJ, Ibdah JA. A Model Incorporating Serum Alkaline Phosphatase for Prediction of Liver Fibrosis in Adults with Obesity and Nonalcoholic Fatty Liver Disease. J Clin Med 2021;10:3311. [PMID: 34362095 DOI: 10.3390/jcm10153311] [Reference Citation Analysis]
134 Gadiparthi C, Spatz M, Greenberg S, Iqbal U, Kanna S, Satapathy SK, Broder A, Ahmed A. NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States. J Clin Transl Hepatol. 2020;8:215-221. [PMID: 32832402 DOI: 10.14218/jcth.2020.00014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
135 Mishra A, Younossi ZM. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:135-144. [PMID: 25755422 DOI: 10.1016/s0973-6883(12)60102-9] [Cited by in Crossref: 51] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
136 Seo S, Maganti K, Khehra M, Ramsamooj R, Tsodikov A, Bowlus C, McVicar J, Zern M, Torok N. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl. 2007;13:844-847. [PMID: 17029282 DOI: 10.1002/lt.20932] [Cited by in Crossref: 127] [Cited by in F6Publishing: 98] [Article Influence: 9.1] [Reference Citation Analysis]
137 Calvert VS, Collantes R, Elariny H, Afendy A, Baranova A, Mendoza M, Goodman Z, Liotta LA, Petricoin EF, Younossi ZM. A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology 2007;46:166-72. [DOI: 10.1002/hep.21688] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
138 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285. [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x] [Cited by in Crossref: 1806] [Cited by in F6Publishing: 1692] [Article Influence: 180.6] [Reference Citation Analysis]
139 Gentili A, Daviddi G, De Vuono S, Ricci MA, Di Filippo F, Alaeddin A, Mannarino MR, Boni M, Vaudo G, Lupattelli G. Non-alcoholic fatty liver disease fibrosis score and preclinical vascular damage in morbidly obese patients. Dig Liver Dis 2016;48:904-8. [PMID: 27160697 DOI: 10.1016/j.dld.2016.04.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
140 Ferrer Márquez M, Carvia Pousaillè C, Velasco Albendea J, Rico Morales MDM, Casado Martín M, Belda Lozano R, Ferrer Ayza M. Influencia de la cirugía bariátrica en esteatosis hepática no alcohólica. Evaluación histológica. Cirugía Española 2009;86:94-100. [DOI: 10.1016/j.ciresp.2009.04.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
141 Reha JL, Lee S, Hofmann LJ. Prevalence and Predictors of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery: A Department of Defense Experience. The American Surgeon 2014;80:595-9. [DOI: 10.1177/000313481408000624] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
142 Naser B, Liske E. Liver failure associated with the use of black cohosh for menopausal symptoms. Medical Journal of Australia 2009;190:99-100. [DOI: 10.5694/j.1326-5377.2009.tb02292.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
143 Allman M, Wallace M, Gaskin L, Rivera CA. Leptin induces an inflammatory phenotype in lean Wistar rats. Mediators Inflamm 2009;2009:738620. [PMID: 20150963 DOI: 10.1155/2009/738620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
144 Rivera CA. Risk factors and mechanisms of non-alcoholic steatohepatitis. Pathophysiology 2008;15:109-14. [PMID: 18667295 DOI: 10.1016/j.pathophys.2008.04.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
145 Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases.Transl Gastroenterol Hepatol. 2020;5:16. [PMID: 32258520 DOI: 10.21037/tgh.2019.09.08] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 61.0] [Reference Citation Analysis]
146 Cao X, Gu Y, Bian S, Zhang Q, Meng G, Liu L, Wu H, Zhang S, Wang Y, Zhang T, Wang X, Sun S, Wang X, Jia Q, Song K, Niu K. Association between eating speed and newly diagnosed nonalcoholic fatty liver disease among the general population. Nutr Res 2020;80:78-88. [PMID: 32736293 DOI: 10.1016/j.nutres.2020.06.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
147 de Castro CA, dos Santos Dias MM, da Silva KA, dos Reis SA, da Conceição LL, De Nadai Marcon L, de Sousa Moraes LF, do Carmo Gouveia Peluzio M. Liver Biomarkers and Their Applications to Nutritional Interventions in Animal Studies. In: Patel VB, Preedy VR, editors. Biomarkers in Liver Disease. Dordrecht: Springer Netherlands; 2017. pp. 129-52. [DOI: 10.1007/978-94-007-7675-3_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
148 Al Akwaa A, El Zubier A, Al Shehri M. Pattern of liver function tests in morbidly obese Saudi patients undergoing bariatric surgery. Saudi J Gastroenterol 2011;17:252-5. [PMID: 21727731 DOI: 10.4103/1319-3767.82579] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
149 Estep JM, Goodman Z, Sharma H, Younossi E, Elarainy H, Baranova A, Younossi Z. Adipocytokine expression associated with miRNA regulation and diagnosis of NASH in obese patients with NAFLD. Liver Int. 2015;35:1367-1372. [PMID: 24684403 DOI: 10.1111/liv.12555] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
150 Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, Massard J, Bonyhay L, Tahiri M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V; LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:34. [PMID: 17096854 DOI: 10.1186/1471-230x-6-34] [Cited by in Crossref: 186] [Cited by in F6Publishing: 71] [Article Influence: 12.4] [Reference Citation Analysis]
151 Brunt EM. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Seminars in Diagnostic Pathology 2005;22:330-8. [DOI: 10.1053/j.semdp.2006.04.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 3.6] [Reference Citation Analysis]
152 Leite NC, Salles GF, Cardoso CR, Villela-Nogueira CA. Serum biomarkers in type 2 diabetic patients with non-alcoholic steatohepatitis and advanced fibrosis. Hepatol Res 2013;43:508-15. [PMID: 23067270 DOI: 10.1111/j.1872-034X.2012.01106.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
153 Alisi A, Manco M, Devito R, Nobili V. Fatty Liver Disease. In: Freemark M, editor. Pediatric Obesity. New York: Springer; 2010. pp. 201-22. [DOI: 10.1007/978-1-60327-874-4_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
154 Cichoż-Lach H, Celiński K, Prozorow-Król B, Swatek J, Słomka M, Lach T. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Med Sci Monit 2012;18:CR735-40. [PMID: 23197236 DOI: 10.12659/msm.883601] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
155 Uslusoy HS, Nak SG, Gülten M. Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. World J Hepatol 2011; 3(8): 219-227 [PMID: 21954411 DOI: 10.4254/wjh.v3.i8.219] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
156 Liew PL, Lee WJ, Wang W, Lee YC, Chen WY, Fang CL, Huang MT. Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity. Obes Surg. 2008;18:847-853. [PMID: 18459024 DOI: 10.1007/s11695-007-9355-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
157 Zatu MC, van Rooyen JM, Loots du T, Greeff M, Schutte AE. A comparison of the cardiometabolic profile of black South Africans with suspected non-alcoholic fatty liver disease (NAFLD) and excessive alcohol use. Alcohol 2015;49:165-72. [PMID: 25543202 DOI: 10.1016/j.alcohol.2014.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
158 Teixeira AR, Bellodi-Privato M, Carvalheira JB, Pilla VF, Pareja JC, D'Albuquerque LA. The incapacity of the surgeon to identify NASH in bariatric surgery makes biopsy mandatory. Obes Surg 2009;19:1678-84. [PMID: 19789933 DOI: 10.1007/s11695-009-9980-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
159 Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T;  JSG-NAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586-595. [PMID: 22328022 DOI: 10.1007/s00535-012-0533-z] [Cited by in Crossref: 268] [Cited by in F6Publishing: 232] [Article Influence: 29.8] [Reference Citation Analysis]
160 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97. [DOI: 10.1016/j.metabol.2018.11.014] [Cited by in Crossref: 165] [Cited by in F6Publishing: 162] [Article Influence: 82.5] [Reference Citation Analysis]
161 Praveenraj P, Gomes RM, Kumar S, Karthikeyan P, Shankar A, Parthasarathi R, Senthilnathan P, Rajapandian S, Palanivelu C. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery. Obes Surg. 2015;25:2078-2087. [PMID: 25835982 DOI: 10.1007/s11695-015-1655-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 5.4] [Reference Citation Analysis]
162 Wernberg CW, Ravnskjaer K, Lauridsen MM, Thiele M. The Role of Diagnostic Biomarkers, Omics Strategies, and Single-Cell Sequencing for Nonalcoholic Fatty Liver Disease in Severely Obese Patients. J Clin Med 2021;10:930. [PMID: 33804302 DOI: 10.3390/jcm10050930] [Reference Citation Analysis]
163 Yoneda M, Imajo K, Takahashi H, Ogawa Y, Eguchi Y, Sumida Y, Yoneda M, Kawanaka M, Saito S, Tokushige K, Nakajima A. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. J Gastroenterol 2018;53:181-96. [PMID: 29177681 DOI: 10.1007/s00535-017-1414-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 9.5] [Reference Citation Analysis]
164 Bozzetto L, Prinster A, Cocozza S, Rivellese AA, Annuzzi G. Role of type 2 diabetes mellitus in nonalcoholic fatty liver disease. European Journal of Clinical Investigation 2011;41:1368-1368. [DOI: 10.1111/j.1365-2362.2011.02542.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
165 Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, McCullough A, Goodman Z, Younossi ZM. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58:3017-3023. [PMID: 23775317 DOI: 10.1007/s10620-013-2743-5] [Cited by in Crossref: 152] [Cited by in F6Publishing: 144] [Article Influence: 19.0] [Reference Citation Analysis]
166 Pan MH, Lai CS, Tsai ML, Ho CT. Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. Mol Nutr Food Res. 2014;58:147-171. [PMID: 24302567 DOI: 10.1002/mnfr.201300522] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 7.4] [Reference Citation Analysis]
167 Moretto M, Kupski C, da Silva VD, Padoin AV, Mottin CC. Effect of bariatric surgery on liver fibrosis. Obes Surg. 2012;22:1044-1049. [PMID: 22108808 DOI: 10.1007/s11695-011-0559-y] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 8.7] [Reference Citation Analysis]
168 Aguilar-olivos NE, Almeda-valdes P, Aguilar-salinas CA, Uribe M, Méndez-sánchez N. The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. Metabolism 2016;65:1196-207. [DOI: 10.1016/j.metabol.2015.09.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 11.0] [Reference Citation Analysis]
169 Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. The American Journal of Clinical Nutrition 2007;86:285-300. [DOI: 10.1093/ajcn/86.2.285] [Cited by in Crossref: 256] [Cited by in F6Publishing: 236] [Article Influence: 18.3] [Reference Citation Analysis]
170 Gentileschi P, Venza M, Benavoli D, Lirosi F, Camperchioli I, D'Eletto M, Lazzaro A, Stolfi VM, Anselmo A, Di Lorenzo N, Tisone G, Gaspari AL. Intragastric balloon followed by biliopancreatic diversion in a liver transplant recipient: a case report. Obes Surg. 2009;19:1460-1463. [PMID: 19506982 DOI: 10.1007/s11695-009-9877-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
171 Kappus M, Abdelmalek M. De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation. Clinics in Liver Disease 2017;21:321-35. [DOI: 10.1016/j.cld.2016.12.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
172 Naveau S, Lamouri K, Pourcher G, Njiké-Nakseu M, Ferretti S, Courie R, Tranchart H, Ghinoiu M, Balian A, Prévot S. The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD. Obes Surg. 2014;24:1693-1701. [PMID: 24841950 DOI: 10.1007/s11695-014-1235-9] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
173 Wenk KS, Arrington KC, Ehrlich A. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol. 2011;25:383-391. [PMID: 20840346 DOI: 10.1111/j.1468-3083.2010.03841.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
174 Barros F, Setúbal S, Martinho JM, Ferraz L, Gaudêncio A. CORRELATION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND FEATURES OF METABOLIC SYNDROME IN MORBIDLY OBESE PATIENTS IN THE PREOPERATIVE ASSESSMENT FOR BARIATRIC SURGERY. Arq Bras Cir Dig 2016;29:260-3. [PMID: 28076482 DOI: 10.1590/0102-6720201600040011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
175 Alqahtani SA, Golabi P, Paik JM, Lam B, Moazez AH, Elariny HA, Goodman Z, Younossi ZM. Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. Obes Surg 2021;31:2002-10. [PMID: 33616848 DOI: 10.1007/s11695-020-04996-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
176 de Cleva R, Duarte LF, Crenitte MRF, de Oliveira CPM, Pajecki D, Santo MA. Use of noninvasive markers to predict advanced fibrosis/cirrhosis in severe obesity. Surgery for Obesity and Related Diseases 2016;12:862-7. [DOI: 10.1016/j.soard.2015.11.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
177 Hossain N, Stepanova M, Afendy A, Nader F, Younossi Y, Rafiq N, Goodman Z, Younossi ZM. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). Scand J Gastroenterol. 2011;46:479-484. [PMID: 21114431 DOI: 10.3109/00365521.2010.539251] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
178 Ferrer Márquez M, Mar Rico Morales MD, Carvia Pousaillè C, Gálvez Miras A, Casado Martín M, Velasco Albendea J, Ferrer Ayza M. Prevalencia y factores asociados a la esteatohepatitis no alcohólica en pacientes obesos sometidos a cirugía bariátrica. Cirugía Española 2008;84:313-7. [DOI: 10.1016/s0009-739x(08)75041-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
179 Doycheva I, Patel N, Peterson M, Loomba R. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. J Diabetes Complications. 2013;27:293-300. [PMID: 23312215 DOI: 10.1016/j.jdiacomp.2012.10.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]